Richard Marais

This inventor holds 26 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 6 EPO patents, primarily in Cancer Therapeutics. Top assignees: Cancer Research Technology Limited, Institute of Cancer Research: Royal Cancer Hospital (the), The Institute of Cancer Research: Royal Cancer Hospital. Active years: 1998-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Marais. Retrieved from https://idiyas.com/inventor/richard-marais

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 3)

% Patents Active = 42.3

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 5.0

ph-index = 8

Forward Citations = 171(Granted Patents)

Location History:

Greater London, GB (2014)
London, GB (1998 - 2017)
Manchester, GB (2017 - 2024)

Company Filing History:

14 out of 269

Cancer Research Technology Limited

patents

10 out of 13

Institute of Cancer Research: Royal Cancer Hospital (the)

patents

9 out of 54

The Institute of Cancer Research: Royal Cancer Hospital

patents

4. 4 out of 62

Cancer Research Campaign Technology Limited

patents

5. 3 out of 3

The Wellcome Trust Limited

patents

6. 2 out of 126

Astex Therapeutics Limited

patents

where one patent can have more than one assignee

Years Active: 1998-2024

Loading Chart...

Areas of Expertise:

Lysyl Oxidase Inhibitors

Methylamine Derivatives

RAF Inhibitors

Pyrido Compounds

Aryl-Quinolyl Compounds

Prodrugs

B-Raf Mutation Detection

Therapeutic Compounds

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12060360 - Lysyl oxidase inhibitors (2024-08-13),

2. 11608330 - Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer (2023-03-21),

3. 11325915 - Lysyl oxidase inhibitors (2022-05-10),

4. 10995088 - Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer (2021-05-04),

5. 10807974 - Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer (2020-10-20),

6. 10167282 - 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer (2019-01-01),

7. 9820976 - 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy (2017-11-21),

8. 9725447 - 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer (2017-08-08),

9. 9540372 - Pyrido[2,3-b]pyrazin-8-substituted compounds and their use (2017-01-10),

10. 9439893 - 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy (2016-09-13),

11. 9155737 - Pyrido[2,3-B]pyrazin-8-substituted compounds and their use (2015-10-13),

12. 9120789 - 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy (2015-09-01),

13. 8912191 - Pyrido[2,3-B]pyrazin-8-substituted compounds and their use (2014-12-16),

14. 8815896 - 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy (2014-08-26),

15. 8580497 - Methods for detection of the oncogenic T1796A B-Raf mutation (2013-11-12),

Title: Richard Marais - Innovator in Cancer Treatment

Introduction

Richard Marais, a prominent inventor based in London, GB, has made significant contributions to the field of cancer research through his innovative inventions. With an impressive portfolio of 26 patents, his work focuses on developing novel treatments targeting lysyl oxidase enzymes.

Latest Patents

Among his latest patents, Richard's inventions include compounds serving as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family inhibitors. These compounds show promise in treating conditions mediated by LOX and LOXL, particularly in various forms of cancer. One notable invention includes a LOX inhibitor aimed at cancers associated with EGFR, along with methods for identifying biomarkers that predict patient responsiveness to these inhibitors. Additionally, he has developed methylamine derivatives that also function as lysyl oxidase inhibitors for cancer treatment, further expanding the therapeutic options available in oncology.

Career Highlights

Throughout his career, Richard has worked with esteemed organizations such as Cancer Research Technology Limited and the Institute of Cancer Research: Royal Cancer Hospital. His work in these institutions has facilitated advancements in cancer therapies and has significantly enhanced research efforts in understanding and combating the disease.

Collaborations

Richard has collaborated with notable professionals in the field, including Caroline Joy Springer and Dan Niculescu-Duvaz. These partnerships have fostered an environment of innovation and have contributed to the successful development of his patents and research projects.

Conclusion

Richard Marais stands out as a leading inventor in the realm of cancer research, driven by his commitment to developing effective treatments. With his extensive patent portfolio and collaborative efforts, he continues to impact the healthcare industry and improve therapeutic options for patients battling cancer.

Profile summary based on public USPTO records.